57332-84-0

Basic information

• Product Name: Ethyl 3-bromo-2-oxobutyrate
• Synonyms: Ethyl 3-bromo-2-oxobutyrate;3-Bromo-2-oxobutanoic acid ethyl ester;3-Bromo-2-oxo-butyric acid ethyl ester;Ethyl 3-bromo-2-oxobutanoate;Ethyl α-BroMoethylglyoxalate;3-bromo-2-keto-butyric acid ethyl ester
• CAS NO: 57332-84-0
• Molecular Formula: C₆H₉BrO₃
• Molecular Weight: 209
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 57332-84-0.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 213℃
• Flash Point: 83℃
• Appearance: /
• Density: 1.474
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform, Ethyl Acetate (Slightly), Methanol (Slightly)
• CAS DataBase Reference: Ethyl 3-bromo-2-oxobutyrate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-bromo-2-oxobutyrate(57332-84-0)
• EPA Substance Registry System: Ethyl 3-bromo-2-oxobutyrate(57332-84-0)

Safety Data

• Hazardous Substances Data: 57332-84-0(Hazardous Substances Data)

Usage

Description

Ethyl 3-bromo-2-oxobutyrate, also known as Ethyl α-bromoethylglyoxalate, is a chemical compound with the molecular formula C7H9BrO3. It is a clear, colorless oil at room temperature and is used in the synthesis of various chemical compounds, particularly in the field of pharmaceuticals and medical imaging.

Uses

Used in Pharmaceutical Industry:
Ethyl 3-bromo-2-oxobutyrate is used as a key intermediate in the synthesis of potential positron emission tomography (PET) tracers for neuropeptide Y Y1 receptors. These tracers are essential for studying the role of neuropeptide Y Y1 receptors in various physiological and pathological processes, including obesity, anxiety, and depression.
Used in Medical Imaging:
In the field of medical imaging, Ethyl 3-bromo-2-oxobutyrate is used as a precursor for the development of PET tracers. PET is a non-invasive imaging technique that allows for the visualization of molecular processes within the body. The tracers synthesized using Ethyl 3-bromo-2-oxobutyrate can help researchers and clinicians better understand the function and distribution of neuropeptide Y Y1 receptors, which can be crucial for the diagnosis and treatment of related conditions.
Chemical Properties:
Ethyl 3-bromo-2-oxobutyrate is a clear, colorless oil with the chemical formula C7H9BrO3. It is a stable compound at room temperature and can be easily manipulated in various chemical reactions due to its functional groups. Its chemical properties make it a versatile building block for the synthesis of more complex molecules, particularly in the pharmaceutical and medical imaging industries.

Synthesis Reference(s)

The Journal of Organic Chemistry, 67, p. 1102, 2002 DOI: 10.1021/jo010630z

Upstream product

• 15933-07-0 Ethyl 2-oxobutanoate 
• 52089-54-0 ethyl 2-hydroxybutyrate 
• 56-23-5 tetrachloromethane 
• 600-18-0 2-Oxobutyric acid 
• 141-78-6 ethyl acetate 

Downstream Products

• 137267-44-8 ethyl 2,5-dimethylthiazole-4-carboxylate 
• 72054-60-5 2-amino-5-methylthiazole-4-carboxylic acid ethyl ester 
• 132089-40-8 ethyl 5-methyl-2-phenylthiazole-4-carboxylate 
• 197719-33-8 5-methyl-4-ethoxycarbonyl-4-oxazolin-2-one 
• 505073-37-0 ethyl 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 505073-86-9 ethyl 2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 796875-23-5 ethyl 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 796875-25-7 ethyl 1-(5-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 505073-79-0 ethyl 2-(2,4-dichlorophenyl)-5-methyl-1-(4-(trifluoromethyl)phenyl)-1H-imidazole-4-carboxylate 
• 572889-87-3 ethyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 
• 796875-43-9 ethyl 5-(bromomethyl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazole-4-carboxylate 
• 796875-44-0 ethyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-(fluoromethyl)-1H-imidazole-4-carboxylate 
• 867314-48-5 5-methyl-2-(3-methylbenzyl)-1,3-thiazol-4-carboxylic acid ethyl ester 
• 866598-56-3 ethyl 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate 

Relevant articles and documents

Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis

In this study, a series of 49 five-membered heterocyclic compounds containing either a pyridine- or a pyrrole-type nitrogen were synthesized and tested against Mycobacterium tuberculosis. Among them, only the 1,3,5-trisubstituted pyrazoles 5-49 exhibited

AMINOAZOLE DERIVATIVE

A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (Ra)n-A- (CR13R14)0-1—(CR11R12)0-1; A represents aryl, heteroaryl; R1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R31R32NCO—; R4 and R5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.

Melanin-Concentrating Hormone Receptor 1 Antagonists Lacking an Aliphatic Amine: Synthesis and Structure-Activity Relationships of Novel 1-(Imidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one Derivatives

Aiming to discover melanin-concentrating hormone receptor 1 (MCHR1) antagonists with improved safety profiles, we hypothesized that the aliphatic amine employed in most antagonists reported to date could be removed if the bicyclic motif of the compound scaffold interacted with Asp123 and/or Tyr272 of MCHR1. We excluded aliphatic amines from our compound designs, with a cutoff value of pKa 8, and explored aliphatic amine-free MCHR1 antagonists in a CNS-oriented chemical space limited by four descriptors (TPSA, ClogP, MW, and HBD count). Screening of novel bicyclic motifs with high intrinsic binding affinity for MCHR1 identified the imidazo[1,2-a]pyridine ring (represented in compounds 6a and 6b), and subsequent cyclization of the central aliphatic amide linkage led to the discovery of a potent, orally bioavailable MCHR1 antagonist 4-[(4-chlorobenzyl)oxy]-1-(2-cyclopropyl-3-methylimidazo[1,2-a]pyridin-6-yl)pyridin-2(1H)-one 10a. It exhibited low potential for hERG inhibition and phospholipidosis induction as well as sufficient brain concentration to exert antiobesity effects in diet-induced obese rats.